Mi­rati teams with Sanofi on PhI/II tri­al for KRAS treat­ment com­bo; Ab­b­Vie los­es in lat­est Hu­mi­ra biosim­i­lar de­vel­op­ment

Mi­rati and Sanofi on Fri­day an­nounced their new non-ex­clu­sive, clin­i­cal col­lab­o­ra­tion to eval­u­ate com­bin­ing Mi­rati’s in­ves­ti­ga­tion­al KRAS G12C in­hibitor ada­gra­sib with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER